US regulators inspect Dr Reddy's, other Indian pharma majors (updated)

Laurus Labs

05/12/2023 10:20

(Adds details, share move)
    By Rishika  Sadam and Kashish Tandon
       HYDERABAD, Dec 5 (Reuters) - 
    The U.S. Food and Drug Administration is inspecting Dr
Reddy's  REDY.NS  research and development centre in the
southern Indian city of Hyderabad, the pharma company said on
Tuesday.
    "We confirm the commencement of a USFDA inspection at our
R&D centre (Integrated Product Development Organisation or
IPDO)," a Reddy's spokesperson told Reuters.
        A unit of Laurus Labs'  LAUL.NS  subsidiary Laurus
Synthesis in Vizag, a city in the southern state of Andhra
Pradesh, is also being inspected by the U.S. drug regulator,
according to a source familiar with the matter.
        Rivals Sun Pharma's  SUN.NS  Dadra facility and Torrent
Pharmaceuticals Ltd's  TORP.NS  oncology unit are also
undergoing FDA inspections, CNBC-TV18 reported.
        Sun Pharma, Laurus and Torrent did not immediately reply
to Reuters' requests seeking comment.
        Torrent Pharma closed 1.6% lower following the news,
while Laurus Labs ended 0.9% down. Sun Pharma and Dr. Reddy's
settled 0.7% and 0.4% higher, respectively.
  
        
  
                          
  

 (Reporting by Rishika  Sadam in Hyderabad, Kashish Tandon in
Bengaluru; Editing by Sonia Cheema and Sohini Goswami)
 ((Rishika.S@thomsonreuters.com;))